[Anticoagulation: assessment of benefits and risks].

Abstract

Thromboembolism is a frequent complication of atrial fibrillation. As could be demonstrated by several placebo-controlled prospective studies in the recent years the rate of thromboembolism was reduced significantly by anticoagulation of nearly all kinds of atrial fibrillation. These results are challenging to weigh risks and benefits in every patient. The principles which have to consider in this calculation are discussed with regard to the knowledge derived from the controlled studies.